Lonza has developed Amaxa nucleofector kits for the transfection of primary mouse B cells from single reactions up to 96-well transfections.
Scientists can now perform experiments with the specific primary cell that is most suitable to their experimental model.
Results of up to 74 per cent transfection efficiency for stimulated mouse B cells and a viability of 59 per cent for human hepatocytes, 120 hours post nucleofection, have been achieved.
Primary cells are suited to study functionality and disease-related phenomena in the physiologically most relevant system.
Due to the lack of an easy-to-use and reliable transfection system, so far most of these studies have been performed on cell lines rather than on the more appropriate primary cell.
Amaxa nucleofector kits are also available for the transfection of human hepatocytes and human chondrocytes.
